Unknown

Dataset Information

0

Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.


ABSTRACT:

Purpose

The generalisability of randomised controlled trials (RCTs) may be limited by restrictive entry criteria or by their experimental nature. Observational research can provide complementary findings but is prone to bias. Employing propensity score matching, to reduce such bias, we compared the real-life effect of cinacalcet use on all-cause mortality (ACM) with findings from the Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) RCT in chronic haemodialysis patients.

Methods

Incident adult haemodialysis patients receiving cinacalcet, recruited in a prospective observational cohort from 2007-2009 (AROii; n?=?10,488), were matched to non-exposed patients regardless of future exposure status. The effect of treatment crossover was investigated with inverse probability of censoring weighted and lag-censored analyses. EVOLVE ACM data were analysed largely as described for the primary composite endpoint.

Results

AROii patients receiving cinacalcet (n?=?532) were matched to 1790 non-exposed patients. The treatment effect of cinacalcet on ACM in the main AROii analysis (hazard ratio 1.03 [95% confidence interval (CI) 0.78-1.35]) was closer to the null than for the Intention to Treat (ITT) analysis of EVOLVE (0.94 [95%CI 0.85-1.04]). Adjusting for non-persistence by 0- and 6-month lag-censoring and by inverse probability of censoring weight, the hazard ratios in AROii (0.76 [95%CI 0.51-1.15], 0.84 [95%CI 0.60-1.18] and 0.79 [95%CI 0.56-1.11], respectively) were comparable with those of EVOLVE (0.82 [95%CI 0.67-1.01], 0.83 [95%CI 0.73-0.96] and 0.87 [95%CI 0.71-1.06], respectively).

Conclusions

Correcting for treatment crossover, we observed results in the 'real-life' setting of the AROii observational cohort that closely mirrored the results of the EVOLVE RCT. Persistence-corrected analyses revealed a trend towards reduced ACM in haemodialysis patients receiving cinacalcet therapy.

SUBMITTER: Gillespie IA 

PROVIDER: S-EPMC5033013 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.

Gillespie Iain A IA   Floege Jürgen J   Gioni Ioanna I   Drüeke Tilman B TB   de Francisco Angel L AL   Anker Stefan D SD   Kubo Yumi Y   Wheeler David C DC   Froissart Marc M  

Pharmacoepidemiology and drug safety 20150526 7


<h4>Purpose</h4>The generalisability of randomised controlled trials (RCTs) may be limited by restrictive entry criteria or by their experimental nature. Observational research can provide complementary findings but is prone to bias. Employing propensity score matching, to reduce such bias, we compared the real-life effect of cinacalcet use on all-cause mortality (ACM) with findings from the Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) RCT in chronic haemodialysis pat  ...[more]

Similar Datasets

| S-EPMC11339120 | biostudies-literature
| S-EPMC3407414 | biostudies-literature
| S-EPMC4677456 | biostudies-literature
| S-EPMC4195658 | biostudies-literature
| S-EPMC4347264 | biostudies-literature
| S-EPMC6118075 | biostudies-literature
| S-EPMC4537699 | biostudies-literature
| S-EPMC5939873 | biostudies-other
| S-EPMC11007998 | biostudies-literature
| S-EPMC6636117 | biostudies-literature